Adaptimmune Therapeutics plc said FDA has granted Orphan Drug Designation to SPEAR T-cells targeting MAGE-A4 (Adaptimmune’s ADP-A2M4 program) for the treatment of soft tissue sarcomas.
Elizabeth Comen originally set out to write a book about the wellness industry, but ended up writing a different book altogether.
